Roche moved to enter the booming weight-loss drug market now dominated by Novo Nordisk and Eli Lilly. The Swiss ...

Shares of Novo Nordisk and Eli Lilly slipped in premarket trading Wednesday after Roche said it had landed a $5.3 billion ...

Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...

The setback comes at a crucial time for Novo Nordisk, which had positioned CagriSema as its next-generation weight-loss ...

Makers of the popular obesity treatments Wegovy and Zepbound are cutting prices for people without insurance. Danish ...

Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...

Novo Nordisk announced a direct-to-consumer program that allows patients to buy Wegovy out of pocket at a lower cost.

All drug manufacturers, including Novo Nordisk and Teva Pharmaceuticals , whose medicines are part of the second round of ...

Novo Nordisk stock was down more than 8% Monday morning after the Danish drugmaker shared new data on its next-generation GLP ...

Novo Nordisk is providing direct-to-patient delivery of Wegovy (semaglutide) through the NovoCare Pharmacy program.

After years of calling obesity drug stocks overhyped, a top analyst now sees Novo Nordisk as a big opportunity.

Novo Nordisk (NVO), the company behind popular diabetes and obesity treatments Ozempic and Wegovy, saw its stock rise on Thursday after ...